Piper Sandler analyst Joseph Catanzaro assumed coverage of Mirati Therapeutics with an Overweight rating and $45 price target. The analyst says Krazati continues to gain traction while the company’s pipelines opportunities are starting to crystalize. The firm sees opportunity for a “portfolio of best-in-class/first-in-class precision oncology assets.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics 9.7M share Spot Secondary priced at $27.80
- Mirati Therapeutics price target raised to $62 from $56 at Oppenheimer
- Mirati Therapeutics reports Q2 EPS ($3.04), consensus ($3.17)
- Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
- Mirati Therapeutics announces $250M common stock offering